Cardinal Health (NYSE: CAH) closed yesterday at $31.59. So far the stock has hit a 52-week low of $24.87 and 52-week high of $39.87. Cardinal Health stock has been showing support around 31.02 and resistance in the 32.06 range. Technical indicators for the stock are Bullish and S&P gives CAH a neutral 3 STAR (o...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

The industry's profit growth sharply outpaced the rest of Corporate America the past 10 years, a trend unlikely to change any time soon even if Congress passes the overhaul now on Capitol Hill, experts say.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5127022 for the full story.

Cardinal Health (NYSE: CAH) closed yesterday at $31.59. So far the stock has hit a 52-week low of $24.87 and 52-week high of $39.87. Cardinal Health stock has been showing support around 31.31 and resistance in the 31.79 range. Technical indicators for the stock are Bullish and S&P gives CAH a neutral 3 STAR (o...(Click the story link or go to http://www.marketintelligencecenter.com for the full story)

CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess [...]

(CFN) CareFusion Corporation Enters Agreement with Masimo

CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. 
 
The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.
 
CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate.
 
CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business of Cardinal Health, Inc. (CAH). The spin-off was completed in September 2009 through a pro rata distribution of roughly 81% of CareFusion’s common stock.
 
Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. Hypoxemia, low blood-oxygen levels, can result in brain damage and death. Hyperoxemia, high-blood oxygen levels, can result in permanent eye-damage and blindness. If infusion and respiratory products are developed successfully, the agreement enables CareFusion to use Masimo’s expertise in pulse oximetry technology. This will boost demand for CareFusion infusion and respiratory products which will expand the company’s top-line.
 
Masimo is a market leader in the pulse oximetry monitoring equipment market industry. The company's closest competitors are Haemonetics Corp. (HAE) and Becton, Dickinson and Co. (BDX).
Read the full analyst report on "CFN"
Read the full analyst report on "MASI"
Read the full analyst report on "CAH"
Read the full analyst report on "HAE"
Read the full analyst report on "BDX"
Zacks Investment Research

Spreads were mixed to slightly tighter in the major indices today despite negative breadth in single-names. HY outperformed IG as both indices saw inside days amid low volumes pre-holiday tomorrow. Financials outperformed non-financials but the financials were off their best levels by the close (as we suspect some concerns over Bair's Basel II Bumblings started to be taken seriously).[More...]

Cardinal Health (CAH) reported fiscal first-quarter earnings per share of 54 cents, surpassing the Zacks Consensus Estimate of 43 cents and the year-ago earnings of 47 cents. Sales Total sales in the reported quarter increased 6% year over year to $24.8 billion. Growth was witnessed across all the business segments. Pharmaceutical segment revenues increased 5% year over year [...]

(CAH) Cardinal Health Eclipses Consensus Estimates

Cardinal Health (CAH) reported fiscal first-quarter earnings per share of 54 cents, surpassing the Zacks Consensus Estimate of 43 cents and the year-ago earnings of 47 cents.
 
Sales
 
Total sales in the reported quarter increased 6% year over year to $24.8 billion. Growth was witnessed across all the business segments.
 
Pharmaceutical segment revenues increased 5% year over year to $22.6 billion. Growth was primarily due to higher sales to existing pharmaceutical distribution customers. Sales to bulk customers increased 6% year over year to $11.3 billion. Sales to non-bulk customers increased 5% year over year to $11.2 billion.
 
Medical segment revenues increased 10% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. In addition, the CareFusion Corp. (CFN) spin-off has resulted in immediate revenue recognition from international sales to CareFusion.
 
Margins
 
Cardinal Health registered a minimal contraction in margins. Gross margin declined 10 basis points (bps) year over year to 3.7%. Distribution, selling, general and administrative expenses as a percentage of sales declined 10 bps year over year to 2.4%. Operating margin declined 20 bps year over year to 1.0%.
 
Balance Sheet & Cash Flow
 
Cardinal Health ended the reported quarter with cash and cash equivalents of roughly $1.6 billion, an increase of 30% sequentially. Cash flow from operations was $0.4 billion.
 
Guidance
 
Cardinal Health expects earnings per share to be at the higher end of its prior guidance of $1.90 to $2.
 
Cardinal Health is one of the largest global healthcare companies that helps pharmacies, hospitals and ambulatory care sites to focus on low-cost patient care. The company is also a leading manufacturer of medical and surgical products. The company recently completed the spin-off of its Clinical and Medical Products business to form a subsidiary, CareFusion Corporation. The spin-off was completed through a pro rata distribution of roughly 81% of CareFusion’s common stock.
Read the full analyst report on "CAH"
Read the full analyst report on "CFN"
Zacks Investment Research

Schaeffer's analyst Morgan Searcy takes a look at news on the Street before the market open.

Schaeffer's analyst Morgan Searcy takes a look at news on the Street before the market open.

Two Veteran Wall Street Analysts discuss: (Vern:) SCG, ZMH, HRC; (Val:) CAH, MDT, OMI

Two Veteran Wall Street Analysts discuss: (Vern:) F, TMO, ZMH; (Val:) CAH, MTSC, PDCO

Two Veteran Wall Street Analysts Review the August 29, 2008 Edition of the Value Line Investment Survey